Biotech Targeting Alzheimer’s Disease Advances Toward Phase 1
June 13, 2018 at 04:00 AM EDT
Source: Streetwise Reports 06/13/2018 Having secured a manufacturing partner for its proprietary antibody candidate, this precision medicine company charts progress toward a Phase 1 trial in Alzheimer’s disease. ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB), in a [...]
